View by Specialty

Headline News

View more

Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma

May 13, 2024
1 min read
Save

Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma

Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma

Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of its phase 3 trial for the adjuvant treatment of patients with resected high-risk melanoma, the company announced in a press release.

View more Headline News

Resources

View more

Food is Medicine

View more Resources
View more Meeting News

Podcasts

View more
Practice Management, Retina/Vitreous 22005361_Healio Minute_OG_1200x630
Hematology/Oncology Oncology Overdrive
May 02, 2024
32 min listen

Innovation in Industry with Sean Bohen, MD

View more Podcasts

Blogs & Columns

View more
A closer look at drug discoveries and developments that affect clinical practice.
Philip A. Bain, MD FACP

Clinical Pearls for the Frontline PCP

with Philip A. Bain, MD, FACP
Practical advice and clinical workflows on medical conditions that are frequently seen in primary care.
View more Blogs & Columns